Five Chinese CGT Biotechs Secure New Funding and Advance Clinical Pipelines

Recently,NEWISH Announces Completion of Tens of Millions of Yuan in Series B1 Financing. This round of financing was jointly invested by domestic well-known institutions Broadcom Capital, Xic Investment, and Excellence Meijia. The funds will mainly be used to advance the clinical Phase I and II studies of the core pipeline.

NEWISH is a biotech company specializing in the research and development of innovative gene therapies and other fields. With a unique commercial perspective, it focuses on unmet clinical needs and continuously advances First-in-class nucleic acid drugs with full independent intellectual property rights, known as "China Original" innovations. The company...Relying on the jointly built STARi (Super Targeted Activation of T-cell Immune Response) nucleic acid drug development platform, NEWISH is developing a new generation of therapeutic cancer vaccines. Currently, the company is mainly focused on unmet clinical niches such as cervical precancerous lesions and postoperative recurrence of liver cancer. Several new drugs have entered the clinical development stage, includingTherapeutic DNA gene drug for liver cancer, NWRD06, received IND approval in May 2023; Therapeutic DNA gene drug for HPV, NWRD08, in October 2023.Received IND approval.Clinical trial results show that NWRD08 demonstrates significant advantages in both safety and efficacy. Administered via injection into the deltoid muscle of the upper arm, the drug not only avoids the trauma and potential risks associated with traditional surgery but also reduces the severity of the condition in a relatively short period, promoting the clearance of the E6E7 gene or the virus.It is believed that as subsequent clinical trials continue to progress, these two therapeutic gene vaccine drugs will bring good news to a large number of patients with precancerous cervical lesions and hepatocellular carcinoma.

Recently,A company focused on innovative gene therapies for neurodegenerative diseases,Origin to De Biomedical Co., Ltd. (hereinafter referred to as "Source to Virtue Bio"） announced the completion of its Pre-A round of financing. This round was led by the Hong Kong Biotechnology Fund under Shanghai Industrial Capital, with participation from Nan Fung Life Tech, the Hong Kong University of Science and Technology Entrepreneurship Fund, and other institutions including well-known family offices in Hong Kong. The funds will be used for the research and development of gene-editing therapies targeting familial Alzheimer's disease.

Source to Virtue BioFounded in 2023, relying on years of scientific research accumulation and academic achievement transformation from the National Key Laboratory of Neurological Diseases at the Hong Kong University of Science and Technology and the Hong Kong Center for Neurodegenerative Diseases, Editact has pioneered the development of a "one-to-many" gene-editing therapy targeting the unmet clinical need of Familial Alzheimer's Disease (FAD), which is expected to be developed into a clinical treatment that cures FAD at its root. Meanwhile, in May 2024, with the support of the Hong Kong University of Science and Technology, the company successfully received funding from the first batch of RAISe+ "Industry-Academia-Research 1+" Program by the Hong Kong Innovation and Technology Commission.

7Month15Day, Fuzhou Tuoxin Tiancheng Biotechnology Co., Ltd. (Drimmunity / Tcelltech) AnnounceCompleteAchievementRecently4000Million USDBRound of Financing. This round of financing was led by SDIC Fund Management,A well-known insurance capital and Hetang Venture Capital followed up on the investment., and has received strong support from institutions such as Xingye Guoxin Asset Management and Fuzhou Mindu Talent Fund.Chenglin Capital served as the exclusive financial advisor for this financing.. The funds raised in this round will be mainly used to support the company's core pipelineCell Therapy DrugsTX-103Sino-US Clinical Development, the development of other pipeline projects, global team expansionExpand, andAccelerate the international strategic layout and advancement of the companyBDCooperation。

TX-103Is the world's first product to enter the registration clinical trial and conduct international clinical trialsB7-H3 CAR-TCell therapy products for recurrent glioblastoma (rGBM) and other solid tumors。Glioblastoma (GBM) is the most common primary intracranial malignant tumor, with approximately4.5NEWISH1.1Ten thousand people, almost all patients relapsed after first-line standard treatment. The median survival period of relapsed patients (mOS) Only6-8months, and the recurrence is more aggressive with a lack of effective subsequent treatment options, representing a significant unmet clinical need. TX-103In the early clinical trials, it has demonstrated excellent efficacy and safety, which canrGBMPatientmOSSignificantly prolonged, with a significant increase in one-year survival rate`, and is well-tolerated, with the potential to break through the bottleneck of existing therapies.`，Currently, it is being carried out globallyI Clinical trial phase. In addition, based on the founding team's deep expertise and global leadership in tumor immunology, Fuzhou Tuoxin Tiancheng Biotechnology Co., Ltd. is advancing simultaneously.Developing the Next Generation Universal Type/In Vivo Cell Therapy andTCell Connector Platform, striving to buildA globally leading solid tumor immunotherapy platform company。

Enka Therapeutics was founded by Professor Tian Zhigang from the University of Science and Technology of China.The team is focused on the research and development and production of innovative cell-based drug technologies based on NK cells, committed to providing patients with more effective and safer precision immunotherapy solutions.In March 2020, with the strong support of the Shanghai Municipal Government, Zhangjiang Management Committee, and Zhangjiang Group, NKCell Therapeutics settled in the Zhangjiang Cell Industrial Park. In 2024, two NK cell products from NKCell Therapeutics have successively obtained clinical trial (IND) approvals from the U.S. FDA and China's CDE. NKCell Therapeutics has achieved a transformation from laboratory to industrialization and made a leap from preclinical to clinical stages, with Phase I clinical trials of its NK cell products currently being conducted in an orderly manner. Meanwhile, multiple IIT projects are underway in the fields of autoimmune diseases and neurodegenerative diseases such as Alzheimer's disease.

Recently, Hubei Renxi Science and Technology Innovation Industry Investment Private Fund Management Co., Ltd. (hereinafter referred to as"Renxi Fund"）AndSichuan Ankangkang Biopharmaceutical Co., Ltd.（Hereinafter referred to as"Encore Biotech") reached an investment cooperation. This collaboration not only marks Renxi Fund's continued deep cultivation in the healthcare track but also signifies that Ancarecon has taken a solid step forward in the research and development and industrialization of innovative drugs.

Sichuan Ankangkang Biopharmaceutical Co., Ltd. is dedicated to developing a new generation of oncolytic virus gene therapies, aiming to provide innovative and effective treatment options for cancer patients worldwide.The company owns a core technology platform with independent intellectual property rights and has established a complete industrial chain covering preclinical research, clinical trials, and production. The company has independently built an oncolytic virus drug production center in Chengdu, which can autonomously completeCMC Development and Clinical Trial Drug Production. Based on itsFlavivirus (Flavivirus) Technology Platform,Encan Biotech EstablishedDouble SpearI/II/III Type Oncolytic Virus Innovative Product Pipeline,ThroughOncolysis and Immune Dual Targets, Dual Signal Mechanism, an oncolytic virus drug that induces immune cells to actively and sustainably kill tumor cells.The dual spear developed byType I Oncolytic Virus (DS1-H2-1)As of2024Obtained FDA Approval in One Go(FDA) approval to enter Phase I/II clinical trials for neuroblastoma. The progress of this innovative therapy marks the company's leading position in the global oncolytic virus treatment field, while also paving a new way for the treatment of rare and fatal childhood cancers.Double SpearType III oncolytic virus product has completed most of the R&D work before IND submission, and is currently compiling the data. It is expected to submit a clinical trial IND application to China's CDE this year. Preclinical trials and preliminaryIIT Human Trials Show That Encocan Biotech's ResearchProduct Combines Oncolysis and Immune ActivationThe dual mechanism of T cells demonstrates high therapeutic potential against various tumors, especially for nervous system tumors such as neuroblastoma and glioblastoma, showing an unprecedented high tumor inhibition rate.

E.N.D

Previous article recommendations:(Click the article title below to open the original text)

Stock Price Surges Nearly 800% in a Single Day! This Gene Therapy Anti-Aging Company Expands Its Reach After Technological Breakthrough

Breakthrough in hPSC Culture Process Bottleneck! Systematic Analysis of Key Issues and Countermeasures in Cultivation (Taking iPSC as an Example)

¥93,000/bottle! The pricing of China's first marketed AAV gene therapy drug is announced

New Breakthrough in Cell Technology! Enhanced Static Process Achieves 8.1 Billion iPSCs/m², More Efficient and Cost-Effective

A Gene Therapy Company in China Completes Pre-A Round Financing

Over $2.1 Billion! Keyi Pharmaceuticals' Cell Therapy Drug Goes Global

Delivery Efficiency Increased by 1500 Times! New Delivery Technology Greatly Enhances the Targeting of RNA Drugs

Nearly 100 Million! Sales Performance of the First Mesenchymal Stem Cell Therapy in the U.S. Announced, Company's Stock Price Soars

Nearly $40 Million! A Cell Therapy Company in China Completes Series B Financing

Stock Price Surges Over 700%! A Breakthrough in Cell Therapy Product Achieved

World's First! Bayer Subsidiary Completes First Patient Dosing in iPS Cell Therapy for Primary Photoreceptor Disease

FDA Rejects Approval of World's First Exosome Cell Therapy

6 Hours to Complete CAR-T Preparation, No Chemotherapy Conditioning, 100% Remission with No Severe Side Effects: World's First Triple-Target Hematologic Tumor CAR-T Cell Drug Achieves Milestone Results

Stock Price Surges 515%, a Cell Therapy Company's Core Pipeline Shows Impressive Clinical Data

Breakthrough in AAV Vector Bottleneck: Another Latest Groundbreaking Achievement in Gene Therapy Published in China

Breakthrough in iPS Cell Technology: Production Costs Reduced by Over 90%, Production Cycle Shortened to 3 Weeks